Can You Buy CagriSema Right Now?

Yes. CagriSema is an investigational medicine, and neither the FDA nor European regulators have approved it. Novo Nordisk submitted its application on December 18, 2025, and the company expects a decision during the last quarter of 2026.

That timeline means three things for buyers:

• No pharmacy can fill a CagriSema prescription today. The drug has no approved version to dispense.
• Compounded versions raise red flags. The FDA has said that one of its two ingredients, cagrilintide, cannot legally go into compounded formulations.
• Products labeled “CagriSema” online are not Novo Nordisk’s drug. Nobody has reviewed their contents the way a regulator reviews an approved medicine.

We choose not to sell a product under the CagriSema name for those reasons. When Novo Nordisk gets approval, you will find the real medicine through a licensed prescriber and pharmacy.

What Is CagriSema?

CagriSema is a once weekly injection that combines two compounds in one dose:

• Cagrilintide, a long acting version of amylin, a hormone that slows stomach emptying and increases the feeling of fullness
• Semaglutide, a GLP-1 medicine already approved under the names Wegovy and Ozempic

Novo Nordisk designed the pair so each one works through a different pathway. The FDA filing describes a 2.4mg dose of each ingredient, reached gradually under medical supervision. No approved dosing schedule exists, so anyone searching for a CagriSema dosage chart or starting dose should wait for the official label and a prescriber’s guidance.

Explore the Weight and Metabolism Category

What Did the CagriSema Trials Find?

The REDEFINE 1 trial followed adults with overweight or obesity for 68 weeks. CagriSema produced average weight loss of roughly 20 to 23 percent, depending on how researchers analyzed the data, while placebo produced about 2 to 3 percent. Most side effects involved the digestive system. In that trial, nausea affected 55 percent of the CagriSema group versus about 13 percent on placebo, and constipation and vomiting also appeared more often.

Overall, relatively few participants stopped treatment because of side effects: 5.9 percent on CagriSema versus 3.5 percent on placebo in REDEFINE 1.

CagriSema vs Tirzepatide — What the Head to Head Trials Showed

Two trials compared CagriSema with tirzepatide, and they reached different conclusions because they used different doses.

• Against the top dose of tirzepatide (15mg): CagriSema averaged about 23 percent weight loss versus about 25.5 percent, and it missed its main goal of matching tirzepatide.
• Against a lower dose (5mg): Novo Nordisk reported that CagriSema produced greater weight loss.

So the answer depends on which tirzepatide dose you compare against. Neither result makes CagriSema available today, and tirzepatide remains an approved prescription medicine.

CagriSema vs Retatrutide — Two Different Approaches

	CagriSema	Retatrutide
Developer	Novo Nordisk	Eli Lilly
Mechanism	Amylin analogue plus GLP-1	Triple agonist: GLP-1, GIP, and glucagon
Stage	Filed with the FDA, decision expected late 2026	Late stage trials, FDA decision pending
Approved today	No	No

Nobody has run a head to head trial of the two, so comparing their numbers directly would mislead you. Each uses different receptors, different study populations, and different timelines.

What Are the Side Effects of CagriSema?

In trials, digestive problems appeared most often. Participants reported nausea, vomiting, constipation, and diarrhea, mostly mild to moderate and strongest while the dose was rising. Doctors usually raise the dose slowly for that reason.

Anyone who considers a GLP-1 medicine should talk with a licensed prescriber about their history, especially pancreatitis, gallbladder disease, or kidney problems.

What Can You Do Instead?

Three honest options exist while CagriSema awaits a decision:

1. Talk to a prescriber about approved medicines. Wegovy, Zepbound, and others already carry FDA approval and proven results.
2. Wait for the CagriSema decision. Sign up below, and we will tell you when the news arrives.
3. Browse research compounds. If you study metabolism and fat cell biology as a research subject, our catalog includes documented compounds, each with a batch report.

Get Notified When CagriSema Is Approved

Browse Our Research Categories

Every product in our catalog ships with a batch report, HPLC purity testing, and discreet packaging. These categories connect most closely to what CagriSema visitors search for.

• Weight and Metabolism: compounds studied in fat metabolism and energy research, including AOD 9604, 5-Amino-1MQ, and CBL-514
• New and Trending: the compounds people search for most right now
• Stacks and Bundles: paired compounds in a single order
• Sleep and Growth Hormone: growth hormone releasing peptides, including GHRP-6
• All Peptides: the complete catalog

Shop the Full Catalog

How to Spot an Unsafe “CagriSema” Listing

Online sellers already advertise products with this name. Check these four points before you spend money:

1. The seller claims to sell CagriSema itself. Only Novo Nordisk makes it, and the FDA has not approved it.
2. No batch report appears. A real report matches your exact batch and names the purity method.
3. The page promises results. Any seller who guarantees weight loss is breaking the rules that protect you.
4. No one answers questions. A reputable seller gives you a real way to reach a person.

Frequently Asked Questions

CagriSema where to buy — is it available anywhere?

No. The FDA has not approved CagriSema, and Novo Nordisk expects a decision in late 2026. Until then, no licensed pharmacy can dispense it.

What is CagriSema?

CagriSema is a once weekly injection from Novo Nordisk that combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 medicine.

Is CagriSema FDA approved?

Not yet. Novo Nordisk filed its application in December 2025, and the agency has not announced a decision.

What is CagriSema’s dosage?

No approved dosing schedule exists. Novo Nordisk’s filing describes 2.4mg of each ingredient, reached gradually under medical supervision.

How does CagriSema compare with tirzepatide?

In a trial against tirzepatide 15mg, CagriSema fell short of the main goal. Against a lower 5mg dose, Novo Nordisk reported better results for CagriSema.

How does CagriSema compare with retatrutide?

They use different mechanisms and sit at different stages of approval. No trial compares them directly.

What are the side effects of CagriSema?

Trials reported mostly digestive effects, such as nausea, vomiting, and constipation, which were strongest during dose increases.

Is compounded CagriSema safe?

The FDA has said cagrilintide cannot legally be used in compounding, and compounded products have not undergone FDA review. Use extra caution with any listing that claims otherwise.

Do you sell CagriSema?

No. We do not sell any product under the CagriSema name. You can browse our research catalog through the category links above.

Will you tell me when CagriSema is approved?

Yes. Use the notification button on this page, and we will contact you when approval news arrives.

Browse Before You Decide

Explore our documented research compounds while CagriSema moves through review.

Weight and Metabolism | New and Trending | All Peptides | Contact Us